GeneDx (WGS) CFO Kevin Feeley Sells Shares to Cover Taxes

What Happened
Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), had 717 restricted stock units (RSUs) settle into 717 shares (no purchase price) on 2026-09-01 and sold 372 shares in the open market as a sell-to-cover to satisfy tax withholding. The open-market sale totaled about $31,188 at a weighted average price of $83.84 per share (sales ranged $83.71–$83.84). The Form 4 records the RSU settlement (conversion/exercise) and the related sale.

Key Details

• Transaction date: 2026-09-01 (Form filed 2026-09-03; no late filing indicated).
• Sale: 372 shares disposed in open market at weighted avg $83.84 → proceeds ≈ $31,188. (prices ranged $83.71–$83.84).
• RSU settlement: 717 RSUs converted/settled into 717 shares (reported as derivative exercise/conversion).
• Shares held after transactions: 40,299 shares beneficially owned; additionally holds RSUs for up to 81,326 shares and options for up to 25,906 shares.
• Notable footnotes: sale was a sell-to-cover to satisfy tax withholding on RSU vesting (routine, not a discretionary open-market trade). RSUs represent contingent rights to receive shares for no consideration; vesting schedule noted (6.25% of award vests quarterly; first tranche vested Dec 1, 2022).

Context
This was a routine sell-to-cover following RSU settlement (cashless-style outcome)—common for covering tax liabilities and not necessarily a market-confidence signal. The filing shows an RSU settlement (no cash outlay) and a partial sale to meet withholding; no purchase or discretionary large sale activity by the CFO beyond the tax-related sale.